Department of Urology, Peking University People's Hospital, Beijing 100044, China.
Department of Clinical Epidemiology, Peking University People's Hospital, Beijing 100044, China.
Chin Med J (Engl). 2017 Sep 5;130(17):2082-2087. doi: 10.4103/0366-6999.213416.
There has been no a specific scale to measure quality of life (QOL) for prostate cancer patients receiving androgen deprivation therapy (ADT) to date. This study aimed to develop and initially validate the scale to evaluate QOL for prostate cancer patients receiving ADT.
The scale was developed following international recommendations. Moreover, the items were all generated through literature review and referenced questionnaires. After being reviewed by expert panelists, the revised scale was formed and then completed by a convenience sample of 200 prostate cancer patients from our hospital. Explore factor analysis (EFA) was applied to test the construct validity, then split-half reliability, Cronbach's alpha, and test-retest reliability were applied to assess the reliability and stability of the scale.
The revised scale contained 22 items and a total of 200 participants had completed the scale. One hundred participants were randomly selected from the total 200 participants to perform EFA with varimax rotation on the revised scale, and "hot flashes" item was deleted for low factor loading. We selected only 3 items from each factor, then, the final scale was formed with 18-items. We selected another 100 participants to perform the EFA again on the final scale. It was demonstrated that the structure with 6 factors explained 72.5% of total variance and factor loading value was above 0.40 in all items of the factors. Moreover, the split-half reliability coefficient, Cronbach's alpha, and test-retest reliability coefficient were calculated to be 0.74, 0.63, and 0.89, respectively, exhibiting good reliability on the whole.
The scale was identified to be a valid and reliable instrument to measure QOL for prostate cancer patients receiving ADT. Moreover, further research is needed to overcome the potential drawbacks.
目前尚无专门的量表用于评估接受雄激素剥夺治疗（ADT）的前列腺癌患者的生活质量（QOL）。本研究旨在开发并初步验证用于评估接受 ADT 的前列腺癌患者 QOL 的量表。
该量表是按照国际建议制定的。此外，所有项目均通过文献回顾和参考问卷生成。在经过专家小组审议后，形成了修订后的量表，然后由我院的 200 名前列腺癌患者进行了便利抽样调查。探索性因子分析（EFA）用于检验结构效度，然后进行半分信度、克朗巴赫α系数和重测信度检验，以评估量表的信度和稳定性。
修订后的量表包含 22 个项目，共有 200 名参与者完成了量表。从 200 名参与者中随机抽取 100 名参与者对修订后的量表进行 EFA，并因因子负荷低而删除“热潮红”项目。我们从每个因子中仅选择 3 个项目，然后形成最终的 18 项量表。我们再次从最终量表中选择了另外 100 名参与者进行 EFA。结果表明，6 个因子的结构解释了总方差的 72.5%，所有因子的项目因子负荷值均高于 0.40。此外，半分信度系数、克朗巴赫α系数和重测信度系数分别为 0.74、0.63 和 0.89，总体上具有良好的可靠性。
该量表被确定为一种有效且可靠的工具，用于评估接受 ADT 的前列腺癌患者的 QOL。此外，还需要进一步的研究来克服潜在的缺陷。
